Data from AMYPAD PNHS is now available on the AD Workbench
The EPAD project has an ambitious goal – to revolutionise the way we carry out clinical trials for treatments designed to prevent Alzheirmer’s dementia.
In a interview with the IMI Programme Office, project coordinators Craig Ritchie of the University of Edinburgh and Serge Van der Geyten of Janssen Pharmaceutical explain what the EPAD project has achieved so far and why the project team is like a family.
“I think one of the strengths of EPAD is that we can do analysis across the different interventions, across the different trials, and learn, but without running into the legal boundaries you would normally have because we have created a trusting environment and we have put a system in place that allows us to do that and actually learn across the treatment arms” says Serge Van der Geyten.
If you are interested to know how EPAD is revolutionising clinical trials for dementia, read the IMI article here.
Related posts
